Rybrevant Injection
Product Images NDC 57894-501

5 FDA label images from Janssen Biotech, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rybrevant (NDC 57894-501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rybrevant 01)

Figure 1 (Rybrevant 01)
Packaging label for Rybrevant (amivantamab-vmjw) injection, 350 mg/7 mL (50 mg/mL) for intravenous infusion, single-dose vial. The label includes product usage instructions, storage conditions at 2°C to 8°C, manufacturer's details Janssen Biotech, Inc., product NDC 57894-501-01, and barcode information. It specifies dilution before use and discarding unused portions.*
FDA Label Image

Figure 2 (Rybrevant 02)

Figure 2 (Rybrevant 02)
Kaplan-Meier survival curves comparing the proportion surviving over time (months) for Rybrevant (amivantamab-vmjw) plus lazertinib versus Osimertinib. The graph includes numbers at risk for each treatment group at various time points up to 51 months.*
FDA Label Image

Figure 3 (Rybrevant 03)

Figure 3 (Rybrevant 03)
A Kaplan-Meier survival curve chart illustrating proportion surviving without progression over months, comparing two groups labeled R-CP and CP. The x-axis represents time in months (up to 15), and the y-axis shows the proportion surviving without progression (from 0 to 1). A table below indicates the number at risk for each group at specified time intervals.*
FDA Label Image

Figure 3 (Rybrevant 04)

Figure 3 (Rybrevant 04)
A Kaplan-Meier survival curve graph depicting the proportion of patients surviving without disease progression over 24 months. The graph compares two groups labeled R-CP and CP, with the proportion surviving without progression on the vertical axis and time in months on the horizontal axis. The number of patients at risk for each group is tabulated below the x-axis for specific time points.*
FDA Label Image

Rybrevant 350mg (Rybrevant 05)

Rybrevant 350mg (Rybrevant 05)
Packaging label for Rybrevant (amivantamab-vmjw) Injection, 350 mg/7 mL (50 mg/mL), intended for intravenous infusion. The label states single-dose vial usage with instructions to discard unused portions and dilute before use. It includes storage guidelines, ingredients, manufacturer Janssen Biotech, Inc., barcode, and product of Ireland information. The NDC 57894-501-01 is visible, along with dosing and safety instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.